DiaMedica Therapeutics (NASDAQ:DMAC) Price Target Raised to $10.00

DiaMedica Therapeutics (NASDAQ:DMAC) had its price objective boosted by HC Wainwright from $7.00 to $10.00 in a research note issued to investors on Wednesday,Benzinga reports. HC Wainwright currently has a buy rating on the stock. HC Wainwright also issued estimates for DiaMedica Therapeutics’ Q1 2025 earnings at ($0.18) EPS, Q2 2025 earnings at ($0.18) EPS, Q3 2025 earnings at ($0.18) EPS, Q4 2025 earnings at ($0.18) EPS, FY2025 earnings at ($0.73) EPS, FY2026 earnings at ($0.93) EPS, FY2027 earnings at ($0.92) EPS, FY2028 earnings at ($0.46) EPS and FY2029 earnings at $0.06 EPS.

DiaMedica Therapeutics Price Performance

DiaMedica Therapeutics stock opened at $4.98 on Wednesday. The firm has a market capitalization of $212.95 million, a P/E ratio of -8.89 and a beta of 1.52. The stock has a fifty day moving average price of $5.93 and a two-hundred day moving average price of $5.11. DiaMedica Therapeutics has a 52-week low of $2.14 and a 52-week high of $6.82.

DiaMedica Therapeutics (NASDAQ:DMAC) last announced its quarterly earnings results on Monday, March 17th. The company reported ($0.18) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.17) by ($0.01). On average, equities research analysts predict that DiaMedica Therapeutics will post -0.59 EPS for the current fiscal year.

Institutional Investors Weigh In On DiaMedica Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of DMAC. Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of DiaMedica Therapeutics during the third quarter worth $40,000. Balyasny Asset Management L.P. bought a new stake in DiaMedica Therapeutics during the 4th quarter worth about $79,000. Y Intercept Hong Kong Ltd acquired a new stake in DiaMedica Therapeutics in the 4th quarter valued at about $81,000. Raymond James Financial Inc. bought a new position in shares of DiaMedica Therapeutics in the fourth quarter worth about $83,000. Finally, Bank of Montreal Can acquired a new position in shares of DiaMedica Therapeutics during the fourth quarter worth approximately $84,000. 10.12% of the stock is owned by institutional investors and hedge funds.

About DiaMedica Therapeutics

DiaMedica Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease.